Citation

D'Souza R, Foster GR. Journal of Drug Evaluation 2004; 2(4): 113-127.

Copyright

(Copyright © 2004)

DOI

10.1080/14791130400023643

PMID

unavailable

Abstract

PEG-interferons have improved pharmacokinetics by allowing a once-weekly dosing regimen that provides constant and sustained therapeutic plasma concentrations, and, as a result, a constant and sustained antiviral pressure over the entire dosing period. This in turn, leads to PEG-IFN having significantly improved response rates over conventional IFN in patients suffering from chronic hepatitis B and C, and it is likely that the improved response rates with these new compounds will lead to more patients eradicating these life threatening viruses. © 2004 Parthonon Publishing.

Language: en

Keywords

human; suicide; insomnia; depression; clinical trial; fatigue; article; mental disease; antidepressant agent; autoimmune disease; neutropenia; thrombocytopenia; headache; macrogol; drug mechanism; drug structure; paracetamol; nonhuman; drug safety; placebo; drug blood level; interferon; drug efficacy; drug tolerability; nausea; alpha interferon; hepatitis C; irritability; fever; drug distribution; neurologic disease; side effect; anemia; arthralgia; flu like syndrome; myalgia; ribavirin; alanine aminotransferase; drug absorption; drug half life; drug response; drug elimination; coughing; drug clearance; hepatitis B; hemolytic anemia; malaise; drug dose regimen; monotherapy; drug eruption; eye disease; acute lymphoblastic leukemia; alpha2 interferon; alpha2a interferon; alpha2b interferon; antiviral activity; asparaginase macrogol; blood toxicity; chronic hepatitis; combined immunodeficiency; cytokine; eradication therapy; hair disease; mouth ulcer; pegademase; peginterferon; peginterferon alpha2a; peginterferon alpha2b; penintron; recombinant granulocyte colony stimulating factor; rigor; thyroid disease; virus RNA